GlobalData on MSN2d
GLP-1RA developer Metsera targets $289m IPO
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART ...
Medscape7d
A Guide for Discussing GLP-1s as Obesity Treatments
The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...
IPWatchdog2d
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
Salon7d
Scientists find Ozempic may treat cancer, Alzheimer's and more. Is it hype or truly a "wonder drug?"
Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules ... So it turns out that GLP-1 drugs may be able to target and ease the low-grade local inflammation of the synovium that causes ...
Investing10d
Viking Therapeutics stock gains traction with standout dual-agonist VK2735 efficacy data
Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only targets GLP-1. Viking's Phase 2 VENTURE study demonstrated promising ...
Investing10d
Viking Therapeutics stock gains traction with standout dual-agonist VK2735 efficacy data
Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only targets GLP-1. Viking's Phase 2 VENTURE study demonstrated promising ...